ArticleGlobal cardiology science & practice2014
The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases.
Article in Global cardiology science & practice, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 18 citations in OpenAlex.
- The effects of sildenafil on ciliary beat frequency in patients with pulmonary non-tuberculous mycobacteria disease: phase I/II trial.BMJ open respiratory research · 2020Trial
- A Novel Approach Combining Ultrasound-Induced Drug-Free Vasodilation and Photoacoustic Monitoring of Vascular Responses.Annals of biomedical engineering · 2026Article
- A novel phosphodiesterase target as a therapeutic approach: inhibiting DEN-induced hepatocellular carcinoma progression.EXCLI journal · 2025Review
- Current Overview of the Biology and Pharmacology in Sugen/Hypoxia-Induced Pulmonary Hypertension in Rats.Journal of aerosol medicine and pulmonary drug delivery · 2024Review
- In vivo noninvasive systemic myography of acute systemic vasoactivity in female pregnant mice.Nature communications · 2023Article
- Management of Pulmonary Arterial Hypertension in the Pediatric Patient.Current cardiology reports · 2019Review
- Sildenafil Prevents Marfan-Associated Emphysema and Early Pulmonary Artery Dilation in Mice.The American journal of pathology · 2019Article
- Phosphodiesterase type 5 and cancers: progress and challenges.Oncotarget · 2017Review
- Nitric oxide and pulmonary arterial hypertension.Global cardiology science & practice · 2017Review
- Role of prostacyclin in pulmonary hypertension.Global cardiology science & practice · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phosphodiesterase inhibitors (PDE) can be used as therapeutic agents for various diseases such as dementia, depression, schizophrenia and erectile dysfunction in men, as well as congestive heart failure, chronic obstructive pulmonary disease, rheumatoid arthritis, other inflammatory diseases, diabetes and various other conditions. In this review we will concentrate on one type of PDE, mainly PDE5 and its role in pulmonary vascular diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.